

Low-level Circulation of Enterovirus D68—Associated Acute Respiratory Infections, Germany, 2014

Janine Reiche, Sindy Böttcher, Sabine Diedrich,
Udo Buchholz, Silke Buda, Walter Haas,
Brunhilde Schweiger, Thorsten Wolff

We used physician sentinel surveillance to identify 25 (7.7%) mild to severe infections with enterovirus D68 (EV-D68) in children and adults among 325 outpatients with acute respiratory infections in Germany during August–October 2014. Results suggested low-level circulation of enterovirus D68 in Germany. Viruses were characterized by sequencing viral protein (VP) 1 and VP4/VP2 genomic regions.

Enterovirus D68 (EV-D68) belongs to the family *Picornaviridae*, genus *Enterovirus*, species *Enterovirus D*. Since its initial discovery in 1962 (1), EV-D68 infections in humans have been reported rarely. However, since 2008, clusters of acute respiratory infections (ARIs) associated with EV-D68 have been reported worldwide, including Europe (2–5).

During mid-August 2014–January 2015, the United States and Canada had nationwide outbreaks of EV-D68 infections associated with severe respiratory disease (6,7). The US Centers for Disease Control and Prevention and state public health laboratories confirmed 1,153 persons in 49 states and the District of Columbia infected by EV-D68 (8). Over the same period, >200 specimens tested were positive for EV-D68 throughout Canada (7). Clinical symptoms ranged from mild to severe disease requiring intensive care and mechanical ventilation. Children were predominantly affected, in particular if they had asthma or wheezing (6,9). After ARIs, symptoms of neurologic illness or acute flaccid myelitis developed in an increasing number of children (10,11).

To describe EV-D68 circulation in a large country in Europe in the fall of 2014, we investigated specimens from patients with respiratory illness for EV-D68. This investigation was conducted within the national outpatient ARI sentinel surveillance in Germany.

The Study

Nasal swab specimens from outpatients with influenza-like illness (ILI), ARI, or both were collected by sentinel physicians participating in sentinel surveillance in Germany

Author affiliation: Robert Koch Institute, Berlin, Germany

DOI: <http://dx.doi.org/10.3201/eid2105.141900>

during weeks 32–44 in 2014 and sent to the Robert Koch Institute (Berlin, Germany). All specimens were tested in parallel for respiratory viruses, including influenza viruses A and B, rhinovirus/enterovirus, respiratory syncytial virus, adenovirus, and metapneumovirus by specific real-time reverse transcription PCRs (online Technical Appendix, <http://wwwnc.cdc.gov/EID/article/21/5/14-1900-Techapp1.pdf>). The rhinovirus/enterovirus real-time PCR detected rhinovirus at a limit of detection of 26 copies/reaction. EV-D68 was identified at a slightly lower sensitivity of 118 copies/reaction.

Rhinovirus/enterovirus–positive specimens were screened for EV-D68 by sequencing the viral protein (VP) 4/VP2 gene regions. Rhinovirus/enterovirus–negative specimens and samples without sequencing results were additionally analyzed by using a specific EV-D68 PCR (12). VP4/VP2 and VP1 regions were sequenced (GenBank accession nos. KP189380–KP189403 and KP657730–KP657747) for EV-D68–positive specimens.

Rhinovirus/enterovirus was detected in 44% (143/325) of the specimens; 98 were identified as rhinovirus types A–C and 25 as EV-D68. The remaining 20 specimens could not be subtyped, but were negative for EV-D68 by using the specific PCR. The proportion of EV-D68 corresponded to 7.7% of the study collective. EV-D68 was initially detected from week 36 (August) through 38 (September) and continuously from week 41 through week 44 in October (Figure 1).

In addition to the other viruses tested, EV-D68–positive specimens were screened for parainfluenza virus 1–4, coronaviruses (NL63, OC43, HKU1, 229E), and bocavirus. None of these viruses was detected in EV-D68–positive patients, which suggested that EV-D68 played a major role in causing respiratory disease.

Major symptoms associated with EV-D68 infection included sudden onset, fever/shivers, cough, and sore throat (Table 1). Pneumonia was diagnosed in a 7-year-old boy and a 10-year-old girl, and a 2-year-old girl was hospitalized because of obstructive bronchitis. For 11 (44%) of 25 case-patients, a concurrent chronic condition was reported: 5 with a respiratory condition, 3 with a cardiac condition, 2 with diabetes, and 1 with a neurologic disorder. EV-D68 was detected in 10 children and 15 adults; 56% of these patients were male.

Patients infected with EV-D68 came from different federal states in Germany; no epidemic cluster or outbreak




Figure 1. Detection of enterovirus D68 (EV-D68), Germany, week 32–44, 2014.

was detected in the context of these patients. Syndromic surveillance data of corresponding sentinel practices showed only a partial coincidence of EV-D68–positive pa-

tients and an increase of ARI activity in the practice. However, the increase in ARI activity was probably caused by unrelated RV activity.

Table 1. Demographic and clinical characteristics of 25 patients infected with enterovirus D68, Germany, weeks 32–44, 2014*

Patient	Week†	Age, y/sex	Federal state	Sudden onset of disease	Fever/shivers	Cough	Sore throat	Clinical follow-up	Admission to hospital	Underlying condition
1	36	6/F	Thuringia	+	+	+	+	ILI	No	None
2	36	42/M	North Rhine-Westphalia	+	+	+	+	ILI	No	Respiratory system
3	37	61/M	North Rhine-Westphalia	+	+	+	+	ILI	No	Cardiac system
4	37	42/F	North Rhine-Westphalia	–	+	+	+	ARI	No	Respiratory system
5	38	11/M	Thuringia	+	+	+	+	ILI	No	None
6	40	35/F	Lower Saxony	+	+	+	–	ILI	No	Respiratory system, diabetes
7	40	53/M	North Rhine-Westphalia	+	+	+	+	ILI	No	Cardiac system
8	41	2/M	Thuringia	+	+	+	–	ILI	No	None
9	41	62/M	Hesse	+	–	+	+	ARI	No	None
10	41	7/M	Rheinland-Palatinate	+	+	+	+	Pneumonia	No	Respiratory system
11	42	8/F	Bavaria	NA	NA	+	+	ARI	No	None
12	42	25/M	Hesse	+	–	+	–	ARI	No	None
13	42	22/M	Lower Saxony	+	+	+	+	ILI	No	None
14	42	14/F	Baden-Württemberg	–	–	+	+	ARI	No	None
15	42	43/M	Bavaria	+	–	+	+	ARI	No	None
16	42	10/F	Berlin	–	+	+	+	Broncheal pneumonia	No	Respiratory system
17	43	3/F	North Rhine-Westphalia	+	+	+	–	ILI	No	None
18	43	12/F	Bavaria	+	–	+	+	ARI	No	None
19	43	52/M	Lower Saxony	+	+	+	+	ILI	No	Diabetes
20	43	26/M	North Rhine-Westphalia	+	+	+	–	ILI	No	None
21	43	44/M	North Rhine-Westphalia	+	–	+	+	ARI	No	Cardiac system
22	43	2/F	Hesse	+	+	+	–	Obstructive bronchitis	Yes	None
23	43	41/M	Saarland	+	+	+	+	ILI	No	None
24	44	2/F	Schleswig-Holstein	+	–	+	–	ARI	No	None
25	44	73/F	North Rhine-Westphalia	–	–	+	+	ARI	No	Neurologic disorder

*+, positive; ILI, influenza-like illness; –, negative; ARI, acute respiratory infection; NA, not available.

†Data are listed by week of symptom onset.

Sequence analysis is not regularly performed for rhinovirus/enterovirus–positive specimens within sentinel surveillance in Germany. However, comparative data can be provided for week 36 through week 20 for the 2009–10 and 2010–11 seasons (Table 2). During those seasons, patients with ILI in 5 age groups (<1–4, 5–15, 16–34, 35–60, and >60 years) were investigated by using the rhinovirus/enterovirus real-time reverse transcription PCR. Within the seasons, an average of 21% (198/952 for 2009–10) and 13% (128/1002 for 2010–11) of specimens were positive for rhinovirus/enterovirus (Table 2). At least 20% of the rhinovirus/enterovirus–positive specimens were arbitrarily chosen for sequencing (mainly RV A, B, or C; 1 echovirus), but no EV-D68 was identified.

Phylogenetic analysis of EV-D68 strains detected in Germany was conducted for the VP1 and the VP4/VP2 genomic regions (Figure 2). Analysis placed EV-D68 isolates from Germany into major groups 1 or 3 and clustered with strains from the United States and the Netherlands from 2014, which indicated circulation of similar strains in the United States and Europe.

Conclusions

In the 2014 outbreak in the United States, ≈36% (2,600) of specimens were positive for EV-D68; children were predominantly affected. Because testing was prioritized for children with severe respiratory illness, there were probably more cases of mild infections (8). Information on EV-D68 circulation during this period for Europe is rare. This finding might be caused by insufficient sampling of patients with ARI or limited detection of EV-D68 by laboratory diagnostics (9). Sporadic cases of neurologic disease after EV-D68 infection were reported from France and the United Kingdom (9,10).

Investigation for EV-D68 has been continuously performed in the Netherlands since the increase in infections in

2010 (13). The ILI/ARI sentinel system in the Netherlands identified 24 EV-D68 infections in 2010, none in 2011, 7 in 2012, 3 in 2013, and 5 in 2014 (by week 40) (13,14), which probably increased toward the end of that year (9). For the 2014 season, a hospital in the Netherlands reported an increase of EV-D68; 16 patients were infected (12). Such an increase in EV-D68 infections was already seen in 2010 at the same hospital along with an increased number of cases throughout the country (13). This finding increased the possibility that an increase in EV-D68 infections in primary care will also extend to increased numbers of infections in patients in secondary care. So far, we report low EV-D68 circulation in Germany: 25 sporadic cases in 2014.

Clinical patterns in patients in Germany were largely determined by the ILI/ARI case definition for collecting specimens. Most (88%) patients had mild disease. Severe disease was observed in 3 children who had obstructive bronchitis and pneumonia, and 1 child required hospital care. Similarly, mild respiratory disease was predominantly observed for patients in the Netherlands (14). However, more severe cases were detected among hospitalized children who had life-threatening respiratory illness, as described in the United States (6,12,14). More than half of patients with severe respiratory illness in Germany and the Netherlands had concurrent conditions (12,14), which seem to be a major factor for development of severe disease after EV-D68 infection (6).

Phylogenetic analysis of EV-D68 from Germany showed high similarity with current strains from the United States and the Netherlands (12,14). These new genetic clusters reflect the evolution of EV-D68 and might be associated with an increasing activity of this virus. For an improved understanding of the factors determining local and temporal differences in respiratory disease outbreaks, continuous collection of global data by representative surveillance systems is needed.

Table 2. Detection of rhinovirus and enterovirus by national outpatient ARI sentinel surveillance, Germany, weeks 36–20, 2009–2010 and 2010–2011*

Age group, y	No. specimens tested	No. rhinovirus/enterovirus–positive specimens (%)	No. rhinoviruses/enteroviruses sequenced	No. rhinoviruses detected	No. enteroviruses detected
2009–2010					
<1–4	156	45 (29)	11	11	0
5–15	386	71 (18)	18	17	1†
16–34	225	40 (18)	12	12	0
35–60	157	34 (22)	19	19	0
>60	28	8 (29)	4	4	0
Total	952	198 (21)	64	63	1
2010–2011					
<1–4	271	56 (21)	21	21	0
5–15	363	40 (11)	20	20	0
16–34	189	20 (11)	17	17	0
35–60	153	12 (9)	11	11	0
>60	26	0 (0)	0	0	0
Total	1,002	128 (13)	69	69	0

*ARI acute respiratory infection.

†Echovirus 9.




Figure 2. Phylogenetic analysis of selected enterovirus D68 (EV-D68) strains based on nucleotide sequences of A) partial viral protein (VP) 4/VP2 region (357 nt) corresponding to nt 733–1089 in the Fermon strain (GenBank accession no. AY426531); and B) partial VP1 region (339 nt) corresponding to nt 2521–2859 in the Fermon strain. Trees were constructed by using maximum-likelihood estimation (Tamura 3-parameter with 5 gamma distributed rates among sites) with 1,000 replicates through MEGA 5.2 (<http://www.megasoftware.net/>). The Fermon strain was used as an outgroup. Reference sequences were selected from the United States, countries in Europe, and other regions, mainly during 2005–2014. Selected reference sequences are not identical in both trees because complementary VP1 and VP4/VP2 sequence data are not available for all reference viruses. Major groups 1, 2, and 3 are shown as described by Meijer et al. (13,14). Only bootstrap values >65% are shown at branch nodes. EV-D68 strains from Germany are indicated in bold. Scale bars indicate nucleotide substitutions per site. Some parts of the trees are collapsed. For an expanded version of Figure 2, see the online Technical Appendix (<http://wwwnc.cdc.gov/EID/article/21/5/14-1900-Techapp1.pdf>).

Acknowledgments

We thank all primary care physicians for participating in the national ARI sentinel surveillance system and technical staff, especially Susi Hafemann and Berit Lenz, for expert technical assistance.

Dr. Reiche is a staff scientist in the Division of Influenza Viruses and Other Respiratory Viruses, National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany. Her research focuses on molecular epidemiology and characterization of respiratory viruses and evaluation of diagnostic methods.

References

- Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. *Am J Epidemiol*. 1967;85:297–310.
- Imamura T, Fuji N, Suzuki A, Tamaki R, Saito M, Aniceto R, et al. Enterovirus 68 among children with severe acute respiratory infection, the Philippines. *Emerg Infect Dis*. 2011;17:1430–5.
- Centers for Disease Control and Prevention. Clusters of acute respiratory illness associated with human enterovirus 68—Asia, Europe, and United States, 2008–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60:1301–4.
- Rahamat-Langendoen J, Riezebos-Brilman A, Borger R, van der Heide R, Brandenburg A, Scholvinck E, et al. Upsurge of human enterovirus 68 infections in patients with severe respiratory tract infections. *J Clin Virol*. 2011;52:103–6. <http://dx.doi.org/10.1016/j.jcv.2011.06.019>
- Lauinger IL, Bible JM, Halligan EP, Aarons EJ, MacMahon E, Tong CY. Lineages, sub-lineages and variants of enterovirus 68 in recent outbreaks. *PLoS ONE*. 2012;7:e36005. <http://dx.doi.org/10.1371/journal.pone.0036005>
- Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, et al. Severe respiratory illness associated with enterovirus D68—Missouri and Illinois, 2014. *MMWR Morb Mortal Wkly Rep*. 2014;63:798–9.
- National Collaborating Centre for Infectious Diseases. Disease debrief: EV-D68 [cited 2014 Nov 5]. <http://www.nccid.ca/disease-debrief-ev-d68#Q1>
- Centers for Disease Control and Prevention. Enterovirus D68 in the United States, 2014 [cited 2014 Nov 13]. <http://www.cdc.gov/non-polio-enterovirus/outbreaks/EV-D68-outbreaks.html>
- European Centre for Disease Prevention and Control. Rapid risk assessment: enterovirus 68 detected in the USA, Canada and Europe, second update [cited 2014 Nov 24]. <http://www.ecdc.europa.eu/en/publications/Publications/Enterovirus-68-detected-in-the-USA-Canada-Europe-second-update-25-November-2014.pdf>
- Lang M, Mirand A, Savy N, Henquell C, Maridet S, Perignon R, et al. Acute flaccid paralysis following enterovirus D68 associated pneumonia, France, 2014. *Euro Surveill*. 2014;19:20952.
- Centers for Disease Control and Prevention. Notes from the field: acute flaccid myelitis among persons aged ≤ 21 years—United States, August 1–November 13, 2014. *MMWR Morb Mortal Wkly Rep*. 2015;63:1243–4.
- Poelman R, Scholvinck EH, Borger R, Niesters HG, van Leer-Buter C. The emergence of enterovirus D68 in a Dutch University Medical Center and the necessity for routinely screening for respiratory viruses. *J Clin Virol*. 2015;62:1–5. <http://dx.doi.org/10.1016/j.jcv.2014.11.011>
- Meijer A, van der Sanden S, Snijders BE, Jaramillo-Gutierrez G, Bont L, van der Ent CK, et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. *Virology*. 2012;423:49–57. <http://dx.doi.org/10.1016/j.virol.2011.11.021>
- Meijer A, Benschop K, Donker G, van der Avoort H. Continued seasonal circulation of enterovirus D68 in the Netherlands, 2011–2014. *Euro Surveill*. 2014;19:20935.

Address for correspondence: Thorsten Wolff, Division of Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Seestraße 10, 13353 Berlin, Germany; email: wolff@rki.de



Rates and Risk Factors for Coccidioidomycosis among Prison Inmates, California, USA, 2011

Dr. Charlotte Wheeler
discusses Coccidioidomycosis among
Prison Inmates in California

<http://www2c.cdc.gov/podcasts/player.asp?f=8635793>

Low-level Circulation of Enterovirus D68—Associated Acute Respiratory Infections, Germany, 2014

Technical Appendix

Clinical Specimens and Ethical Statement

Specimens were collected from patients with influenza-like illness/acute respiratory infection by physicians participating in national outpatient acute respiratory infection sentinel surveillance in Germany (1). Sampling was performed only for patients who provided written consent for laboratory examination and for collection of patient-specific data (date of disease onset, sampling date, symptoms, and underlying chronic illness). Specimens were sent to the National Reference Center for Influenza (Berlin, Germany) for national surveillance of influenza and acute respiratory infections in Germany. Analyses of all data were conducted anonymously. National virologic surveillance of influenza and other respiratory viruses was approved by the Ethics Committee of the Charité, Humboldt University, Berlin (EA2/126/11).

Real-Time PCR for Rhinovirus/Enterovirus (EV) and Specific EV-D68 Detection

RNA was extracted from 300- μ L specimens by using the MagAttract Viral RNA M48 Kit (QIAGEN, Hilden, Germany) and eluted in 80 μ L of elution buffer. Alternatively, RNA was extracted by using the RTP DNA/RNA Virus Mini Kit (Invitek, Berlin, Germany) with 400- μ L specimens and an elution volume of 60 μ L. Twenty-five microliters of extracted RNA were subjected to cDNA synthesis by using 200 U M-MLV reverse transcriptase (Invitrogen, Karlsruhe, Germany) in a total volume of 40 μ L (2). The rhinovirus/enterovirus real-time PCR uses primer complementary to regions within the 5'-untranslated region (corresponding to nt 351–558 in the Fermon strain; GenBank accession no. AY426531) and detects rhinovirus with a limit of detection of 26 copies/reaction. This method also detects enterovirus, including strains CV-A9, CV-A10, CV-A16, CV-A21, CV-A24, CV-B1–6, E-4, E-9, E-11, E-20, E-21, E-25, EV-B69, and EV-D68. The limit of detection for EV-D68 was 118 copies/reaction.

Rhinovirus/enterovirus PCR was performed in a 25- μ L reaction mixture that contained 3 μ L of cDNA product, 300 nmol/L of primer pairs rhinovirus/enterovirus–375-F1 (5'-GTG

KYC YAG CCT GCG TGG C-3') and rhinovirus/enterovirus-586-R1 (5'-ACG GAC ACC CAA AGT AGT YGG T-3'), 100 nmol/L of probe rhinovirus/enterovirus-476 (5'-YAK-CCT CCG GCC CCT GAA TGY GGC TAA-BBQ-3'), 0.1 mmol/L dNTP (Invitrogen) with dUTP (GE Healthcare, Munich, Germany), 5 mmol/L MgCl₂ (Invitrogen), 0.5 U Platinum *Taq* DNA polymerase (Invitrogen), and PCR buffer (200 mmol/L Tris-HCl, pH 8.4, 500 mmol/L KCl). Amplification was conducted at 95°C for 5 min, followed by 45 cycles at 95°C for 15 s and 60°C for 30 s. All reactions were conducted by using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany) or LightCycler 480 Real-Time PCR System (Roche Deutschland Holding GmbH, Gernzach, Germany), respectively.

The protocol for detection of EV-D68 was adapted from that of Poelman et al. (3). This protocol uses 300 nmol/L of primer pairs EV-D68 FW (5'-TGT TCC CAC GGT TGA AAA CAA-3') and EV-D68 RV (5'-TGT CTA GCG TCT CAT GGT TTT CAC-3'), and 150 nmol/L of probe EV-D68 (5'-6FAM-WCC GCT ATA GTA CTT CG-MGB-3') in a volume of 25 µL in a 2 step real-time PCR.

Real-Time PCR for Other Respiratory Pathogens

In addition to detection of rhinovirus/enterovirus, all specimens were tested for influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and adenovirus by using in-house real-time PCRs as described (2,4-6). EV-D68-positive specimens were further screened for parainfluenza virus 1-4, coronaviruses (NL63, OC43, HKU1, and 229E), and bocavirus by using 2-step real-time PCRs (oligonucleotide sequences can be provided on request).

Amplification of Viral Protein (VP) 4/VP2 Genome Regions

From rhinovirus/enterovirus-positive specimens, amplification of the VP4/VP2 was performed with 4 µL of cDNA in a 50-µL reaction by using 600 nmol/L of primer rhinovirus/enterovirus-Seq-F2-Out (5'-CGG CCC CTG AAT GCG GCT AA-3'), 900 nmol/L of primer rhinovirus/enterovirus-Seq-9565-R (5'-GCA TCI GGY ARY TTC CAC CAN CC-3') (7), 0.1 mmol/L dNTP (Invitrogen) with dUTP (GE Healthcare), 2 mmol/L mM MgCl₂, 0.5 U Platinum *Taq* DNA polymerase (Invitrogen), and PCR buffer (200 mmol/L Tris-HCl, pH 8.4, 500 mmol/L KCl). Amplification was conducted at 94°C for 5 min; followed by 40 cycles at 94°C for 30 s, 65°C for 30 s, and 72°C for 1 min; and a final extension at 72°C for 10 min. Amplified products (634 bp) were analyzed by electrophoresis on a 1.5% agarose gel.

For samples that had negative results, 4 μL of the external PCR sample was used for a seminested PCR, which was performed in a 50- μL reaction with 300 nmol/L of rhinovirus/enterovirus–Seq-9895-F (5'-GGG ACC AAC TAC TTT GGG TGT CCG TGT-3') (7) and rhinovirus/enterovirus–Seq-9565-R, respectively. The cycling protocol was the same as that for the external PCR except that the annealing temperature was 60°C. Nested amplicons (549 bp) were visualized by using agarose gel electrophoresis.

Sequencing of the VP4/VP2 region was performed for at least 20% of the rhinovirus/enterovirus–positive specimens of all age groups in the seasons 2009/2010 and 2010/2011, respectively. For the 2014 season, sequencing was performed from all specimens, identifying RV A-C and EV-D68. All EV-D68-positive samples were further subjected to amplification of the VP1 gene (online Technical Appendix Table).

Amplification of VP1 Genome Region

VP1 was amplified by using the One-Step-Reverse Transcription PCR Kit (QIAGEN), followed by a nested PCR with HotStarTaq-Mastermix (QIAGEN). Reverse transcription PCR was conducted in a 12.5- μL reaction that contained 2 μL of RNA, 600 nmol/L of primer NRZ 267 (5'-ATG YTA GST ACW CAT RTB GTB TGG GAY TT-3'), 600 nmol/L of NRZ 268 (5'-ATC CAY TGR ATM CCW GGG CCY TCR AAR C-3') according to the manufacturer's protocol. The temperature profile used was 22°C for 10 min, 50°C for 45 min, and 95°C for 15 min, followed by 40 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s. Final elongation conducted at 72°C for 10 min.

Nested PCR was conducted by using 1 μL of reverse transcription PCR samples in a 12.5- μL volume that contained 600 $\mu\text{mol/L}$ of primer NRZ 269 (5'-AAT GCY AAY GTT GGY TAY GTY ACH TGT T-3') and 600 $\mu\text{mol/L}$ of primer NRZ 270 (5'-AAG AYC CYA CAA ARA CYC CHC CRW ARC CKG G-3'). Amplification was conducted by using a touchdown protocol with 10 cycles (94°C for 30 s, 60°C for 30s, and 72°C for 90 s) 10x with a decrease of 1°C/cycle in the annealing temperature, followed by 30 cycles (94°C for 30 s, 50°C for 30 s, and 72°C for 90 s), and final elongation 72°C for 10 min. The resulting amplification product (1,129 bp) was visualized by electrophoresis on a 1.5% agarose gel.

Sequencing

VP4/VP2 amplification products were purified either directly by using the MSB SpinPCRapace Kit (Stratec Molecular, Birkenfeld, Germany) or from agarose gels by using the Invisorb Spin DNA Gel Extraction Kit (Thermo Scientific, Schwerte, Germany) according to manufacturer's instructions. Purified PCR products were cycle sequenced in the forward

and the reverse directions with primer pairs rhinovirus/enterovirus–Seq-F2-Out and rhinovirus/enterovirus–Seq-9565-R or rhinovirus/enterovirus–Seq-9895-F and rhinovirus/enterovirus–Seq-9565-R, respectively, in a 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) by using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).

VP1 amplification products were directly purified by using ExoSAP-IT (Affymetrix, High Wycombe, UK). Sequence reaction was conducted by using primers NRZ 269, NRZ 270, and NRZ 271 (5'-CAA GCA ATG TTY GTA CCH ACT GG-3').

References


1. der Heiden MA, Kopke K, Buda S, Buchholz U, Haas W. Estimates of excess medically attended acute respiratory infections in periods of seasonal and pandemic influenza in Germany from 2001/02 to 2010/11. *PLoS ONE*. 2013;8:e64593. [PubMed](#)
<http://dx.doi.org/10.1371/journal.pone.0064593>
2. Reiche J, Schweiger B. Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. *J Clin Microbiol*. 2009;47:1800–10. [PubMed](#)
<http://dx.doi.org/10.1128/JCM.02286-08>
3. Poelman R, Scholvinck EH, Borger R, Niesters HG, van Leer-Buter C. The emergence of enterovirus D68 in a Dutch university medical center and the necessity for routinely screening for respiratory viruses. *J Clin Virol*. 2015;62:1–5. [PubMed](#)
<http://dx.doi.org/10.1016/j.jcv.2014.11.011>
4. Schulze M, Nitsche A, Schweiger B, Biere B. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. *PLoS ONE*. 2010;5:e9966. [PubMed](#) <http://dx.doi.org/10.1371/journal.pone.0009966>
5. Chmielewicz B, Nitsche A, Schweiger B, Ellerbrok H. Development of a PCR-based assay for detection, quantification, and genotyping of human adenoviruses. *Clin Chem*. 2005;51:1365–73. [PubMed](#) <http://dx.doi.org/10.1373/clinchem.2004.045088>
6. Reiche J, Jacobsen S, Neubauer K, Hafemann S, Nitsche A, Milde J, et al. Human metapneumovirus: insights from a ten-year molecular and epidemiological analysis in Germany. *PLoS ONE*. 2014;9:e88342. [PubMed](#)
<http://dx.doi.org/10.1371/journal.pone.0088342>
7. Savolainen C, Blomqvist S, Mulders MN, Hovi T. Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. *J Gen Virol*. 2002;83:333–40. [PubMed](#)

Technical Appendix Table. Overview and accession numbers of enterovirus D68 sequences by genome region, Germany, 2014*


Specimen†	Accession no., VP4/VP2	Accession no., VP1
GER/16-01/13-14	–	KP657737
GER/10-01/13-14	KP189380	KP189392
GER/10-02/13-14	–	KP657738
GER/10-03/13-14	–	KP657739
GER/16-02/13-14	KP189381	KP189393
GER/09-01/14-15	KP657730	KP657740
GER/10-04/14-15	KP189382	KP189394
GER/16-03/14-15	KP657731	KP657741
GER/07-01/14-15	KP657732	KP657742
GER/11-01/14-15	KP189383	KP189395
GER/02-01/14-15	–	KP657743
GER/07-02/14-15	KP189384	KP189396
GER/09-02/14-15	KP189385	KP189397
GER/11-02/14-15	KP189386	KP189398
GER/02-02/14-15	KP657733	KP657744
GER/03-01/14-15	KP189387	KP189399
GER/10-05/14-15	KP657734	KP657745
GER/02-03/14-15	KP189388	KP189400
GER/09-03/14-15	KP189389	KP189401
GER/10-06/14-15	KP657735	–
GER/10-07/14-15	KP189390	KP189402
GER/15-01/14-15	–	KP657746
GER/07-03/14-15	KP189391	KP189403
GER/12-01/14-15	–	–
GER/10-08/14-15	KP657736	KP657747

*VP, viral protein; –, no sequence was obtained.

†Sequencing of the VP4/VP2 and the VP1 regions was performed with enterovirus D68–positive specimens. Of the 25 specimens, sequences were obtained from 24 specimens, mainly for both genome regions. For 1 specimen (GER/12-01/14-15), no sequencing result was obtained.



Technical Appendix Figure 1. Expansion of phylogenetic analysis of viral protein (VP) 4/VP2 (uncollapsed) of enterovirus D68, Germany, 2014. Scale bar indicates nucleotide substitutions per site.



Technical Appendix Figure 2. Expansion of phylogenetic analysis of viral protein (VP) 1 (uncollapsed) of enterovirus D68, Germany, 2014. Scale bar indicates nucleotide substitutions per site.